Organovo Holdings Inc (ONVO)
$0.45
Live
Performance
- $0.45$0.49$0.45
0.0%
Downside
Day's Volatility :8.14%
Upside
8.14%
- $0.43$2.05$0.45
5.16%
Downside
52 Weeks Volatility :79.18%
Upside
78.05%
Returns
| Period | Organovo Holdings Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -20.07% | 3.6% | 0.0% |
6 Months | -54.37% | 10.2% | 0.0% |
1 Year | -60.21% | 19.6% | 0.0% |
3 Years | -92.41% | 16.8% | -23.0% |
Highlights
Market Capitalization | 7.2M |
Book Value | $0.46 |
Earnings Per Share (EPS) | -1.37 |
PEG Ratio | 0.0 |
Wall Street Target Price | 6.1 |
Profit Margin | 0.0% |
Operating Margin TTM | -8682.05% |
Return On Assets TTM | -73.67% |
Return On Equity TTM | -151.72% |
Revenue TTM | 73.0K |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | -48.0% |
Gross Profit TTM | -8.5M |
EBITDA | -14.0M |
Diluted Eps TTM | -1.37 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.74 |
EPS Estimate Next Year | -1.37 |
EPS Estimate Current Quarter | -0.33 |
EPS Estimate Next Quarter | -0.33 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 1255.56%
Technicals Summary
Sell
Neutral
Buy
Organovo Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Organovo Holdings Inc | 0.51% | -54.37% | -60.21% | -92.41% | -91.62% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Organovo Holdings Inc | NA | NA | 0.0 | -1.74 | -1.52 | -0.74 | NA | 0.46 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Organovo Holdings Inc | Hold | $7.2M | -91.62% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Organovo Holdings Inc
Increasing Revenue
Revenue is up for the last 3 quarters, 5.0K → 39.0K (in $), with an average increase of 54.2% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -3.04M → -3.34M (in $), with an average decrease of 9.8% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 143.1%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 137.2%
Institutional Holdings
Armistice Capital, LLC
6.05%Prescott Group Capital Management LLC
3.09%Vanguard Group Inc
2.30%BlackRock Inc
0.93%Geode Capital Management, LLC
0.72%Citadel Advisors Llc
0.52%
Company Information
organovo (nyse mkt: onvo) designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. the company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. these 3d human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. in addition to numerous scientific publications, their technology has been featured in the wall street journal, time magazine, the economist, and other outlets. organovo is changing the shape of medical research and practice.
Organization | Organovo Holdings Inc |
Employees | 20 |
CEO | Mr. Keith E. Murphy |
Industry | Health Technology |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$0.45
-4.26%
Invesco Bulletshares 2025 Hi
$0.45
-4.26%
Schwab International Dividend Equity Etf
$0.45
-4.26%
Blockchain Coinvestors Acquisition Corp.
$0.45
-4.26%
Allgiant Travel Company
$0.45
-4.26%
Rogers Corp
$0.45
-4.26%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$0.45
-4.26%
Iheartmedia
$0.45
-4.26%
Lightpath Technologies Inc
$0.45
-4.26%